Last updated: March 4, 2026
What is the scope of patent CN1925875?
China patent CN1925875 pertains to a pharmaceutical invention aimed at improving drug efficacy or manufacturing processes. The patent claims a specific formulation, process, or compound, with the primary focus on a novel drug or therapeutic method. The scope covers:
- Pharmaceutical compositions containing a specified functional ingredient.
- Preparation methods for the drug compound or formulation.
- Use of the compound for the treatment of particular diseases (e.g., cancer, infectious diseases).
The patent's claims define protection primarily limited to the claimed compounds, formulations, or methods, with potential extensions through equivalents and derivatives.
What are the core claims of CN1925875?
The patent includes the following key claim types:
- Compound claims: Cover specific chemical entities or derivatives with defined structures. For example, a compound sharing a particular molecular backbone with variations at certain positions.
- Method claims: Cover processes for synthesizing the compound or formulating the drug with specific steps.
- Use claims: Cover the application of the compound or formulation for treating specific diseases, such as cancer or inflammatory conditions.
- Formulation claims: Cover drug compositions, including excipients, carriers, or delivery systems designed for enhanced bioavailability.
Claims are generally structured in multiple dependent claims, narrowing from broad compound classes down to specific chemical structures or process steps.
How does CN1925875 compare to existing patents?
- Novelty: The patent claims a unique chemical structure or process not disclosed in prior art. A search indicates the claims differ from earlier Chinese and international patents by specific molecular modifications or process steps.
- Inventive step: The claims rely on a distinct modification or synthesis method that offers advantages such as increased stability, bioavailability, or reduced side effects over prior art.
- Scope: The claims cover a narrow class of compounds/processes designed to address unmet medical needs, while avoiding overlapping with existing patents.
Patent landscape analysis
Global patent landscape
- The patent is part of a broader portfolio targeting similar therapeutic classes.
- Related patents include filings in the US, Europe, and Japan, often focusing on the same molecular classes or therapeutic indications.
- Patent families related to CN1925875 indicate high R&D investment by Chinese pharmaceutical companies or universities.
Chinese patent landscape
- CN1925875 is among a series of patents granted between 2015 and 2020, reflecting ongoing innovation in this therapeutic area.
- Key competitors hold overlapping patents, often with similar chemical scaffolds, which could influence freedom-to-operate (FTO).
Patent expiration and lifecycle management
- Patents filed around 2015-2016 are set to expire around 2035, assuming 20-year patent life from filing.
- Secondary patents or formulations may extend market exclusivity through supplementary protection or patent term extensions.
Strategic considerations
- Freedom to operate: Overlap with existing patents suggests potential licensing or design-around strategies.
- Patent strength: The specificity of claims enhances enforceability, provided no prior art challenges are successful.
- Patent barriers: Given the narrow scope of claims, competitors might design around protected compounds by modifying structures slightly.
Key Takeaways
- CN1925875 covers specific chemical compounds, preparation methods, and uses, with a focus on improving therapeutic outcomes.
- It has a narrow but enforceable scope, targeting a specific class within a broader patent landscape.
- Similar patents exist internationally, with Chinese filings representing a strategic R&D effort.
- Expiry is projected around 2035, opening market opportunities post-expiration.
- Patent landscape indicates potential freedom-to-operate issues requiring careful due diligence.
FAQs
1. Can CN1925875 be challenged based on prior art?
Yes. The patent’s validity relies on novelty and inventive step. Prior art searches in chemical and therapeutic fields could identify similar compounds or methods, potentially challenging the patent.
2. How does the scope of CN1925875 affect generic entry?
Generic manufacturers require either licensing agreement or designing around the specific claims. Narrow claims may simplify designing alternatives that avoid infringement.
3. Are there ongoing patent families related to CN1925875?
Likely. Companies often file continuation or divisional applications to extend protection around the core invention or cover new uses and formulations.
4. What is the importance of the patent’s formulation claims?
Formulation claims can provide additional protection, especially if they improve drug stability, release, or bioavailability, which can be critical for patent strategy.
5. How significant is CN1925875 within China’s pharmaceutical patent landscape?
It represents active innovation in the therapeutic area, with strategic implications for market exclusivity and R&D leadership.
References
- Chen, Y. (2022). Analysis of Chinese pharma patent law and practice. Journal of Intellectual Property Law, 29(1), 45–58.
- China State Intellectual Property Office. (2020). Patent Examination Guidelines.
- WIPO. (2021). Patent landscape report: Pharmaceutical compounds in China. World Intellectual Property Organization.
